Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07350577 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
A Phase 1 study of Ulcerative Colitis (UC), sponsored by AltruBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07350577: Recruiting Phase 1 study of Ulcerative Colitis (UC), sponsored by AltruBio.
NCT07350577 is a Phase 1 study of Ulcerative Colitis (UC) that is actively recruiting participants, run by AltruBio. The registered enrollment target is 24 participants, below the 763-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07350577, a Phase 1 study of Ulcerative Colitis (UC), is actively recruiting participants, sponsored by AltruBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of intravenously administrated ALTB-268 in healthy participants.
Primary Outcome
\- Numbers of participants with adverse events (AEs): seriousness, severity, relationship to the investigational products, outcome, duration, and management
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL ALTB-268
Study Locations (1)
Florida
- Syneos Health Clinical Research Services, LLC - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-11-17 |
| Est. Completion | 2026-07-28 |
| Phase | Phase 1 |
What NCT07350577 shows while recruiting
NCT07350577 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 763-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07350577 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07350577 about?
NCT07350577 is a clinical study titled "Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants". This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of intravenously administrated ALTB-268 in healthy participants.
What is the current status of trial NCT07350577?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-11-17. Estimated completion is 2026-07-28.
What conditions does trial NCT07350577 study?
This clinical trial studies the following conditions: Ulcerative Colitis (UC).
What interventions are being tested in trial NCT07350577?
The interventions under investigation include: Placebo (OTHER), ALTB-268 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07350577?
This trial is sponsored by AltruBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07350577 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis (UC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07350577's enrollment target sits among peer trials
24 17th of 17 higher than 1 of 17 other Ulcerative Colitis (UC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis (UC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
RECRUITING · Phase 1
-
Early Serum Infliximab Levels in Severe Ulcerative Colitis.
COMPLETED · Phase 1
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RECRUITING
-
Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
RECRUITING · Phase 2
-
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
RECRUITING · NA
-
Evaluation of the SMART IBD App in Pediatric IBD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI